Simon Lovestone is Professor of Old Age Psychiatry at the NIHR Biomedical Research Centre for Mental Health; MRC Centre for Neurodegeneration Research; Departments of Psychological Medicine and Neuroscience, Institute of Psychiatry, King's College, London, UK.

"In 12 studies from a January 2009 conference in Oxford, England, researchers from academia and drug companies review recent results of biomarker research and applications to brain disorders. The use of biomarkers with brain diseases is challenged by the blood-brain barrier and by the brain being protected within the skull. Among the topics are biomarkers, dementia, and public health; imaging biomarkers in Alzheimer's disease; identifying several markers of Alzheimer's disease using quantitative multiplex proteomic immunoassay panels; biomarkers in Huntington's and Parkinson's diseases; and trials and tribulation of biomarkers in oncology. No index is provided." (Book News Inc., February 2011)

• Preface. 1. The Uses of Biomarkers in Drug Development (Orest Hurko).2. Biomarkers, Dementia, and Public Health (C.F. Wright, A. Hall A, F.E. Matthews, and C. Brayne).3. Imaging Biomarkers in Alzheimer's Disease (Natalie Ryan and Nick C. Fox).4. CSF Biomarkers: Pin-pointing Alzheimer pathogenesis (Niklas Mattsson, Kaj Blennow, and Henrik Zetterberg).5. AddNeuroMed: The European Collaboration for the Discovery of Novel Biomarkers for Alzheimer's Disease (Simon Lovestone, Paul Francis, Iwona Kloszewska, Patrizia Mecocci, Andrew Simmons, Hilkka Soininen, Christian Spenger, Magda Tsolaki, Bruno Vellas, Lars-Olof Wahlund, Malcolm Ward, on behalf of the AddNeuroMed consortium).6. MRI Measures of Alzheimer's Disease and the AddNeuroMed Study (Andrew Simmons, Eric Westman, Sebastian Muehlboeck, Patrizia Mecocci, Bruno Vellas, Magda Tsolaki, Iwona Kloszewska, Lars-Olof Wahlund, Hilkka Soininen, Simon Lovestone, Alan Evans, Christian Spenger, for the AddNeuroMed consortium).7. Identifying Early Markers of Alzheimer's disease using Quantitative Multiplex Proteomic Immunoassay Panels (Holly D. Soares, Yu Chen, Marwin Sabbagh, Alex Rohrer, Elisabeth Schrijvers, and Monique Breteler).8. Proteomics for Brain Disorders: The Promise for Biomarkers (Malcolm Ward, Andreas Güntert, James Campbell, and Ian Pi).9. Use of Genetic Variation as Biomarkers for Alzheimer's disease (Christiane Reitz and Richard Mayeux).10. Biomarkers in Huntington's and Parkinson's Disease (Gráinne C. O'Keeffe, Andrew W. Michell, Roger A. Barker).11. Biomarkers in Oncology (Trials and Tribulations: Sheila E. Taube).12. Biomarkers in Alzheimer's Disease: Not Yet Surrogate Endpoints (N. Coley, S. Andrieu, J. Delrieu, T. Voisin, and B. Vellas).

Simon Lovestone is Professor of Old Age Psychiatry at the NIHR Biomedical Research Centre for Mental Health; MRC Centre for Neurodegeneration Research; Departments of Psychological Medicine and Neuroscience, Institute of Psychiatry, King's College, London, UK.

"In 12 studies from a January 2009 conference in Oxford, England, researchers from academia and drug companies review recent results of biomarker research and applications to brain disorders. The use of biomarkers with brain diseases is challenged by the blood-brain barrier and by the brain being protected within the skull. Among the topics are biomarkers, dementia, and public health; imaging biomarkers in Alzheimer's disease; identifying several markers of Alzheimer's disease using quantitative multiplex proteomic immunoassay panels; biomarkers in Huntington's and Parkinson's diseases; and trials and tribulation of biomarkers in oncology. No index is provided." (Book News Inc., February 2011)

• Preface. 1. The Uses of Biomarkers in Drug Development (Orest Hurko).2. Biomarkers, Dementia, and Public Health (C.F. Wright, A. Hall A, F.E. Matthews, and C. Brayne).3. Imaging Biomarkers in Alzheimer's Disease (Natalie Ryan and Nick C. Fox).4. CSF Biomarkers: Pin-pointing Alzheimer pathogenesis (Niklas Mattsson, Kaj Blennow, and Henrik Zetterberg).5. AddNeuroMed: The European Collaboration for the Discovery of Novel Biomarkers for Alzheimer's Disease (Simon Lovestone, Paul Francis, Iwona Kloszewska, Patrizia Mecocci, Andrew Simmons, Hilkka Soininen, Christian Spenger, Magda Tsolaki, Bruno Vellas, Lars-Olof Wahlund, Malcolm Ward, on behalf of the AddNeuroMed consortium).6. MRI Measures of Alzheimer's Disease and the AddNeuroMed Study (Andrew Simmons, Eric Westman, Sebastian Muehlboeck, Patrizia Mecocci, Bruno Vellas, Magda Tsolaki, Iwona Kloszewska, Lars-Olof Wahlund, Hilkka Soininen, Simon Lovestone, Alan Evans, Christian Spenger, for the AddNeuroMed consortium).7. Identifying Early Markers of Alzheimer's disease using Quantitative Multiplex Proteomic Immunoassay Panels (Holly D. Soares, Yu Chen, Marwin Sabbagh, Alex Rohrer, Elisabeth Schrijvers, and Monique Breteler).8. Proteomics for Brain Disorders: The Promise for Biomarkers (Malcolm Ward, Andreas Güntert, James Campbell, and Ian Pi).9. Use of Genetic Variation as Biomarkers for Alzheimer's disease (Christiane Reitz and Richard Mayeux).10. Biomarkers in Huntington's and Parkinson's Disease (Gráinne C. O'Keeffe, Andrew W. Michell, Roger A. Barker).11. Biomarkers in Oncology (Trials and Tribulations: Sheila E. Taube).12. Biomarkers in Alzheimer's Disease: Not Yet Surrogate Endpoints (N. Coley, S. Andrieu, J. Delrieu, T. Voisin, and B. Vellas).

Simon Lovestone is Professor of Old Age Psychiatry at the NIHR Biomedical Research Centre for Mental Health; MRC Centre for Neurodegeneration Research; Departments of Psychological Medicine and Neuroscience, Institute of Psychiatry, King's College, London, UK.

"In 12 studies from a January 2009 conference in Oxford, England, researchers from academia and drug companies review recent results of biomarker research and applications to brain disorders. The use of biomarkers with brain diseases is challenged by the blood-brain barrier and by the brain being protected within the skull. Among the topics are biomarkers, dementia, and public health; imaging biomarkers in Alzheimer's disease; identifying several markers of Alzheimer's disease using quantitative multiplex proteomic immunoassay panels; biomarkers in Huntington's and Parkinson's diseases; and trials and tribulation of biomarkers in oncology. No index is provided." (Book News Inc., February 2011)

• Preface. 1. The Uses of Biomarkers in Drug Development (Orest Hurko).2. Biomarkers, Dementia, and Public Health (C.F. Wright, A. Hall A, F.E. Matthews, and C. Brayne).3. Imaging Biomarkers in Alzheimer's Disease (Natalie Ryan and Nick C. Fox).4. CSF Biomarkers: Pin-pointing Alzheimer pathogenesis (Niklas Mattsson, Kaj Blennow, and Henrik Zetterberg).5. AddNeuroMed: The European Collaboration for the Discovery of Novel Biomarkers for Alzheimer's Disease (Simon Lovestone, Paul Francis, Iwona Kloszewska, Patrizia Mecocci, Andrew Simmons, Hilkka Soininen, Christian Spenger, Magda Tsolaki, Bruno Vellas, Lars-Olof Wahlund, Malcolm Ward, on behalf of the AddNeuroMed consortium).6. MRI Measures of Alzheimer's Disease and the AddNeuroMed Study (Andrew Simmons, Eric Westman, Sebastian Muehlboeck, Patrizia Mecocci, Bruno Vellas, Magda Tsolaki, Iwona Kloszewska, Lars-Olof Wahlund, Hilkka Soininen, Simon Lovestone, Alan Evans, Christian Spenger, for the AddNeuroMed consortium).7. Identifying Early Markers of Alzheimer's disease using Quantitative Multiplex Proteomic Immunoassay Panels (Holly D. Soares, Yu Chen, Marwin Sabbagh, Alex Rohrer, Elisabeth Schrijvers, and Monique Breteler).8. Proteomics for Brain Disorders: The Promise for Biomarkers (Malcolm Ward, Andreas Güntert, James Campbell, and Ian Pi).9. Use of Genetic Variation as Biomarkers for Alzheimer's disease (Christiane Reitz and Richard Mayeux).10. Biomarkers in Huntington's and Parkinson's Disease (Gráinne C. O'Keeffe, Andrew W. Michell, Roger A. Barker).11. Biomarkers in Oncology (Trials and Tribulations: Sheila E. Taube).12. Biomarkers in Alzheimer's Disease: Not Yet Surrogate Endpoints (N. Coley, S. Andrieu, J. Delrieu, T. Voisin, and B. Vellas).